Glucocorticoids (triamcinolone) and dioxins (TCDD) are highly specific teratogens in the mouse, in that cleft palate is the major malformation observed. Glucocorticoids and TCDD both readily cross the yolk sac and placenta and appear in the developing secondary palate. Structure-activity relationships for glucocorticoid-and TCDD-induced cleft palate suggest a receptor involvement. Receptors for glucocorticoids and TCDD are present in the palate and their levels in various mouse strains are highly correlated with their sensitivity to cleft palate induction. Receptors for glucocorticoids appear to be more prevalent in the palatal mesenchymal cells whereas those for TCDD are probably located in the palatal epithelial cells. Glucocorticoids exert their teratogenic effect on the palate by inhibiting the growth of the palatal mesenchymal cells whereas TCDD alters the terminal cell differentiation of the medial palatal epithelial cells.
Glucocorticoid-Induced Cleft Palate
Glucocorticoids administered to several species of experimental animals at midgestation inhibit complete formation of the secondary palate (1) (2) (3) (4) . Development of the mammalian secondary palate is a complex process that depends upon the presence of various hormones and growth factors (5) . The palatal shelves first appear as outgrowths from the maxillary process and subsequently grow in a vertical position alongside the tongue. The shelves undergo a rapid reorientation to the horizontal position above the tongue which brings the apposing epithelia into contact at the midline. The medial epithelial cells then undergo a programmed cell death with resorption ofthe basement membrane and cell remnants, and the two shelves fuse into a single tissue, the secondary palate, which separates the oral and nasal cavities (6, 7) .
Different strains of inbred mice exhibit different degrees of susceptibility to glucocorticoid-induced cleft palate (1, 8) . All of the surviving offspring of A/J mice treated with glucocorticoids between days 11 and 15 of gestation have cleft palate, whereas C57BL/6J mice treated with the same dose produce 20 to 25% offspring with cleft palate (8) (9) (10) . A number of mechanisms have been proposed to explain the different responses of various strains of mice to the teratogenic action of glucocorticoids (5, 11, 12) . Walker and Fraser (6) showed that during normal development, the palatal shelves became horizontal later in the A/J than the C57BL/6J strain and suggested that this difference makes A/J mice more susceptible to cortisone than C57BL/6J mice (13) . A recent study utilizing frozen sections (14) showed that, in addition to delaying palatal shelf elevation, cortisone treatment severely reduced the extent of contact between the palatal shelves in A/J mice. Although contact was present in 20% of the cortisone-treated fetuses, the mean area of the shelf contact was only 20% of that in control palates. Therefore, the net shelf contact in cortisone-treated litters was only 4% of the potential contact in control litters. Other studies in which shelf contact was assessed in glucocorticoid-treated fetuses reported contact in 27-30% of the fetuses. However, this limited contact, observed between the shelves in the midpalate region, was considered adequate for complete palatal fusion, and a failure in the fusion mechanism was proposed as an alternative (4, 15) . Diewert and Pratt (14) also observed shelf contact in the midpalate region; however, the shelves remained separated in the anterior and posterior regions. Since contact between the shelves normally occurs first in the midpalate region, some contact in this region would be expected with cortisone treatment; the presence of a small area of contact in some cortisone-treated palates cannot be considered equivalent to the extensive contact present in controls.
Studies of effects of glucocorticoids on the palatal epithelium suggested that there may be significant differences between tissue responses in vitro and in vivo. Recent investigations of the in vivo effects of triamcinolone on palatal epithelium in the sensitive CF1 mouse line showed that degenerative events were delayed, but not prevented (16, 17) . These results suggested that effects of glucocorticoid on degenerative changes in the epithelium were not responsible for palatal clefting in vivo. However, studies of glucocorticoids in vitro were reported to cause changes in the medial epithelium. Cortisol was reported to prevent medial epithelial breakdown in the sensitive A/J strain, but not in the resistant C57BL/6J strain (18) . Based on the results of previous in vitro studies showing palatal fusion in the presence of hydrocortisone (19, 20) , differences in culture conditions appear to have significant effects on the results. Therefore, although the palatal epithelium may be affected by teratogens in vitro, these effects are not similar to the major effect contributing to development of cleft palate in vivo.
Other possible explanations of strain differences in response to glucocorticoid-induced cleft palate are metabolism, level of endogenous steroids, and differential distribution of the steroid in maternal and fetal tissues. Additionally, there might be differences in sensitivity of embryonic facial structures toward the steroid. Variations in the endogenous levels of glucocorticoids in sensitive and resistant strains were not correlated with the sensitivity of the strains to steroids; there were not significant differences between A/J and C57BL/6J mice in the concentration of maternal or fetal corticosterone during midgestation (21) . Glucocorticoids can cross the rodent placenta without being metabolized. When administered in pharmacologic doses to pregnant mice, a large fraction of the administered steroid reached embryos unmetabolized and appeared to function as the active teratogenic agent (22) .
Glucocorticoid effects in adult and fetal tissues are mediated through the interaction of the hormone with specific intracellular receptor proteins in the cytoplasmic fraction of target cells. Schmidt and Litwack (23) proposed a five-step model for activation of the glucocorticoid-receptor complex. The receptor, which is a protein of 87,000 molecular weight (24) is present in the cytoplasm in a form that is phosphorylated, contains reduced sulfhydryl groups, and is capable of binding glucocorticoid. The unbound receptor may have associated with it a low molecular weight, heat-stable factor that maintains the protein in a conformation favorable for steroid binding and inhibits the subsequent activation. The phosphorylated receptor protein binds glucocorticoid to form an unactivated complex. This complex then undergoes a confonnational change (activation) that results in the exposure of positively charged amino acid residues and hence an increased affinity for polyanions like DNA. During the activation step, the receptor or another component becomes dephosphorylated. Likewise, activation also may involve the dissociation of a low molecular weight, heat-stable factor which, when associated with the receptor, blocks activation. The activated glucocorticoid-receptor complex then translocates to the nucleus where it binds to chromatin acceptor sites and alters the transcription of specific genes. The steroid eventually dissociates from the nuclear receptor protein, and may then be recycled to the cytoplasm where it can be either degraded or reactivated with the heat-stable factor.
The appearance in specific embryonic tissues of cytoplasmic glucocorticoid receptors at discrete developmental stages has been implicated as one factor that determines the appearance of hormonal responsiveness in these tissues (25) . Likewise, the presence of functional nuclear acceptor proteins for the steroid-receptor complex is also required for embryonic target tissues about to undergo hormone-dependent differentiation (26, 27) .
Most evidence suggests that glucocorticoid teratogenicity is due to direct action on the embryo. The total binding of labeled glucocorticoid to palatal and other embryonic tissue proteins varied in different strains of mice and correlated with the teratologic responsiveness of the strains to glucocorticoids. Salomon and Pratt (5, (28) (29) (30) demonstrated that mouse embryonic palatal mesenchyme cells possess high affinity, specific receptor proteins for glucocorticoid. The synthetic glucocorticoids dexamethasone and triamcinolone acetonide (TA) have a higher affinity for these receptors than the natural glucocorticoid hydrocortisone (HC), and a structure-activity study has shown that their affinity correlated well with their teratogenicity (31); TA was found to be 40 times as potent as HC and twice as potent as DEX (32) .
Although the glucocorticoid receptors in embryonic mouse palatal shelves have not been biochemically characterized, various properties of receptors prepared from whole day-13 A/J and C57BL/6J mouse embryos have been studied (32) . Embryonic cytosols from both strains were found to contain high affinity, limited capacity binding proteins for dexamethasone and triamcinolone acetonide, which bind both natural and synthetic glucocorticoids, and can be distinguished from serum corticosteroid binding globulin (transcortin) by their heat sensitivity, sedimentation, gel filtration properties, and sensitivity to sulfhydryl reagents. These embryonic receptor proteins appear to be indistinguishable from adult glucocorticoid receptor protein found in the liver.
Embryonic A/J facial mesenchyme cells, both freshly isolated and in primary culture, possessed two to three times more cytoplasmic receptors than C57BL/6J mesenchyme cells (28) . Strain differences in the concentration of cytoplasmic receptors for glucocorticoids in the day-14 embryo were generally restricted to the orofacial region (5). Several investigators (5, 33, 34) showed that the levels of cytoplasmic glucocorticoid receptor in fetal palate and adult liver cytosols were correlated with sensitivity to glucocorticoid-induced cleft palate. In one case these results were not corroborated. Utilizing whole mouse fetal heads and an unconventional method of cytosol preparation, Hackney (35) (42, 43) . These results are in accord with observations that dexamethasone and cortisone inhibited the in vivo proliferation of mesenchymal cells of rat and mouse palatal processes (3, 44, 45) . This inhibition of mesenchymal cell growth is a key factor in producing glucocorticoid-induced cleft palate (14) which is mediated by a receptor-dependent mechanism, presumably involving altered transcription of a key enzyme or protein in the palate (46) . Recently, Grove et al. (47) provided evidence for a correlation between alteration in phosphatidylinositol turnover at the cell surface and growth inhibition induced by dexamethasone in human palatal mesenchymal cells.
Physiological levels of glucocorticoids (10' M) promote DNA synthesis and stimulate human and mouse palatal mesenchyme cell growth. Therefore, glucocorticoids at physiological concentrations either alone or through interactions with other hormones or growth factors may control certain stages of normal palatogenesis. Dexamethasone administered in vivo to A/J and C57BL/6J mice causes an increase in palatal glutamine synthetase which may be essential for expression of various mesenchymal or epithelial cell surface proteins (48) .
Glucocorticoids are important regulators of carbohydrate, protein, and fat metabolism in adult tissues (49) . Glucocorticoids also perform important functions during various stages of embryonic and fetal development (50) . Glucocorticoids, either alone or with other hormones such as thyroxine, insulin, and growth factors, control the morphological and biochemical differentiation of a variety of fetal and postnatal tissues.
Dioxins and Their Receptors in Teratology
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) serves as the prototype for a large group of halogenated aroma-tic hydrocarbons [chlorinated dibenzo-p-dioxin, dibenzofuran, azo(xy)benzene, biphenyl, and naphthalene isomers and brominated biphenyl isomers], which are all approximate isostereomers, produce a similar and characteristic pattern of toxic and biochemical responses, and are thought to act by a common mechanism (51) (52) (53) .
The administration of TCDD (and congeners) to laboratory animals induces the coordinate expression of a battery of enzymes, including the activity of the cytochrome P450-mediated microsomal monooxygenase aryl hydrocarbon hydroxylase in liver and a variety of other tissues (54) . This pleiotropic response is initiated by the stereospecific, reversible binding of TCDD to a cytosolic protein, termed the induction receptor, and by the translocation of the ligand-receptor complex to the nucleus (55) (56) (57) . In mice there is a genetic polymorphism at the locus that determines the receptor, the Ah locus (58) . Inbred strains of mice carrying the Ahb allele (e.g., C57BL/6J) have a high affinity receptor and are sensitive to the induction of AHH activity by TCDD; other inbred strains possessing the Ahd allele (e.g., DBA/2) have a lower affinity receptor and are less sensitive to enzyme induction by TCDD. In crosses and backcrosses between C57BL/6J and DBA/2 mice, expression of the Ahb allele is either dominant or codominant, depending on the assay used for phenotyping.
The toxic responses produced by halogenated aromatic hydrocarbons are quite characteristic; however, many of the lesions are highly species-specific (59) (60) (61) . Following the administration of a lethal dose of TCDD or one of its congeners virtually all species experience a prolonged wasting syndrome prior to death, with loss of adipose tissue, involution of lymphoid organs, and degeneration of the seminiferous tubules of the testicle. In contrast, the more distinctive lesions involve proliferation and/or metaplasia of epithelial tissues such as skin, stomach, intestines, and urinary tract, and occur in a limited number of species. Similarly, the presence and severity of hepatic pathology vary considerably among species. The cause of death is unknown.
Two independent lines of evidence indicate that the toxic responses to TCDD and its congeners are mediated by their binding to the induction receptor. First, for a large number of halogenated aromatic hydrocarbons, the rank ordered structure-activity relation for their receptor affinity or their potency to induce AHH activity corresponds to their toxic potency (measured as the mean lethal dose, LD50, or dose reported to produce a specific toxic response) (51, 53, 62, 63) . Second, toxic responses produced by TCDD in mice, e.g., thymic involution, cleft palate formation in the fetus, and hepatic porphyria, have been found to segregate with the Ah locus (64, 65) . In DBA/2J, RF/J, AKR/J, SWR/J, and 129/J, the five mouse strains with a low affinity receptor, TCDD produced 0 to 3% incidence of cleft palate. Four of the five strains with a high affinity receptor, C57BL/6J, A/J, BALB/cByJ and SEC/1REJ, developed a 54 to 95% incidence in response to TCDD. CBA/J was the only strain with a high affinity receptor that did not develop cleft palate and these mice are also resistant to cortisone-induced cleft palate (65) . A recent study (66) has shown that ,-naphthoflavone, which is another ligand of the Ah-receptor but which does not produce cleft palate by itself, was found to increase the frequency of TCDD-induced cleft palate when co-administered. In addition to the polysubstrate monooxygenase system, other enzyme systems not related to metabollc conversion of polycyclic hydrocarbons are considered to be structural gene products of the Ah locus. 3-Naphthoflavone may induce a number of enzymes also stimulated by TCDD but in a different pattern and insufficient for cleft palate induction.
Galloway et al. (67) found that the inducible cytochrome P1-450 enzyme system is expressed in mouse embryos explanted from the uterus at day 7.5 or 8.5 of gestation. These results imply that the regulatory gene product (Ah receptor) and the structural gene product (cytochrome P1-450) are both functional from an early embryonic age. The Ah locus is most likely responsible for inducible benzo(a)pyrene metabolism and associated embryotoxicity and teratogenesis in the mouse embryo at or soon after day 7 of gestation.
Dencker and Pratt (68) showed that embryonic palatal shelves from C57BL/6J, a cleft palate-responsive mouse strain (69) , have high levels of a specific cytoplasmic receptor for TCDD with similar biochemical characteristics as the adult liver. A nonresponsive strain, AKR/J, on the other hand, showed no specific TCDD binding in adult liver or any embryonic tissue and was resistant to the induction of cleft palate by TCDD (67) . Studies using frozen sections (70) showed that TCDD-treated C57BL/6J palatal shelves made firm and extensive contact at their medial epithelium in vivo, in contrast with that found with A/J glucocorticoid-treated palatal shelves in vivo (14) . TCDD administered on day 10 (71), at a teratogenic dose for the mouse palate, crossed the visceral yolk sac and/or chorioallantoic placenta and was present in the embryo at nanomolar concentrations, which is similar to the equilibrium binding constant (Kd) found in the palatal shelves (68) .
Therefore, it appears that TCDD exerts a direct effect on the midgestation embryo to produce cleft palate. This effect appears to be limited to an alteration in the complex process of terminal cell differentiation of the medial epithelial cells. The known major effect of TCDD on human beings, i.e., chloracne, has also been ascribed to an effect on epidermal cell differentiation (52) 
